Daiichi Life Insurance Co. Ltd. Purchases Shares of 5,325 Astera Labs, Inc. $ALAB

Daiichi Life Insurance Co. Ltd. acquired a new position in Astera Labs, Inc. (NASDAQ:ALAB) during the second quarter, Holdings Channel reports. The firm acquired 5,325 shares of the company’s stock, valued at approximately $2,572,000.

Several other institutional investors have also modified their holdings of the company. Reflection Asset Management acquired a new position in Astera Labs during the fourth quarter worth about $25,000. Keating Financial Advisory Services Inc. bought a new position in shares of Astera Labs during the 2nd quarter valued at about $25,000. Smartleaf Asset Management LLC grew its stake in shares of Astera Labs by 422.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 188 shares of the company’s stock worth $32,000 after purchasing an additional 152 shares during the last quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA acquired a new position in shares of Astera Labs in the 4th quarter worth approximately $33,000. Finally, Whipplewood Advisors LLC raised its holdings in shares of Astera Labs by 15,950.0% in the 1st quarter. Whipplewood Advisors LLC now owns 321 shares of the company’s stock worth $35,000 after purchasing an additional 319 shares in the last quarter. Institutional investors and hedge funds own 60.47% of the company’s stock.

Insider Activity at Astera Labs

In other news, CEO Jitendra Mohan sold 90,630 shares of the business’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $340.35, for a total transaction of $30,845,920.50. Following the transaction, the chief executive officer directly owned 1,266,665 shares in the company, valued at $431,109,432.75. The trade was a 6.68% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Manuel Alba sold 136,974 shares of the company’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $442.01, for a total transaction of $60,543,877.74. Following the completion of the transaction, the director directly owned 1,287,524 shares in the company, valued at $569,098,483.24. This trade represents a 9.62% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 419,244 shares of company stock worth $163,135,169. 10.40% of the stock is currently owned by company insiders.

Astera Labs Price Performance

NASDAQ:ALAB opened at $284.97 on Monday. The stock has a market cap of $49.44 billion, a PE ratio of 141.07 and a beta of 3.84. Astera Labs, Inc. has a fifty-two week low of $97.89 and a fifty-two week high of $499.48. The stock’s 50-day moving average is $352.70 and its two-hundred day moving average is $245.57.

Astera Labs (NASDAQ:ALAB) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $0.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.69 by $0.11. The business had revenue of $392.40 million during the quarter, compared to analyst estimates of $360.85 million. Astera Labs had a net margin of 30.74% and a return on equity of 19.24%. The firm’s revenue was up 104.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.44 earnings per share. Astera Labs has set its Q3 2026 guidance at 1.160-1.210 EPS. On average, equities research analysts anticipate that Astera Labs, Inc. will post 2.7 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on ALAB. Stifel Nicolaus raised their target price on shares of Astera Labs from $260.00 to $460.00 and gave the stock a “buy” rating in a report on Wednesday, June 24th. Barclays raised their price objective on Astera Labs from $200.00 to $325.00 and gave the stock an “equal weight” rating in a research note on Monday, July 20th. Northland Securities upgraded Astera Labs from a “market perform” rating to an “outperform” rating and set a $350.00 price target for the company in a research report on Monday, August 17th. UBS Group restated a “neutral” rating and issued a $425.00 price target on shares of Astera Labs in a research report on Wednesday, August 5th. Finally, Roth Capital reaffirmed a “buy” rating and issued a $450.00 price objective on shares of Astera Labs in a research note on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and eight have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Astera Labs has a consensus rating of “Moderate Buy” and a consensus target price of $333.00.

About Astera Labs

Astera Labs is a fabless semiconductor company that develops connectivity solutions for data center and cloud infrastructure. The firm focuses on addressing signal integrity and link management challenges that arise as server architectures incorporate higher-bandwidth processors and accelerators. Its technology is aimed at improving reliability and performance for high-speed interconnects used in servers, storage systems and compute accelerators.

The company’s product portfolio centers on silicon devices and accompanying firmware and software that enhance and manage high-speed links.